Nail disease

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

Retrieved on: 
Wednesday, January 31, 2024
Streptomyces, Fungal infection, Investigational New Drug, Venous stasis, Nail disease, Prevalence, IND, HDAC, Dermatophytosis, FDA, Ciclopirox, Onycholysis, Food, Vanda, Onychomycosis, Fungus, Antibiotics

WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
  • Onychomycosis, or tinea unguium, is a fungal infection of the nail.
  • Onychomycosis can result in discoloration of the nail, onycholysis (nail separation from the nail bed), and nail plate thickening.
  • There have not been any new onychomycosis treatments approved by the FDA since 2014.4
    Centers for Disease Control and Prevention.

Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials

Retrieved on: 
Friday, April 7, 2023
Chapter Four, Scabies, Venous ulcer, Intellectual property, Rosacea, Cellulitis, Nail disease, A-Z, Psoriasis, Sun, Research, Directory, Orientation, Confidentiality, Chapter Three, Acne, Chapter One, Dermatology, Wound healing, Diabetic foot ulcer, Chapter Two, Chapter Five, Chapter Six, Smash Mouth, Cosmetics, Hyperlink, Rash, Clothing, Video game, Music, Lease, Veterinary medicine, Risk management, Commercial property, Property management, Dermatitis, Plantar wart, Hair loss, Impetigo, Angioedema

DUBLIN, April 7, 2023 /PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 7, 2023 /PRNewswire/ -- The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dermatology Partnering 2016-2023: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.
  • The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering dermatology deals.
  • The Global Dermatology Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 700 dermatology deals.

2022 Worldwide Psoriatic Arthritis Treatment Industry Epidemiology & Pipeline Analysis Report - by Drug Class, Gender Type, Disease Type, Age Group, Severity Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Pharmaceutical, Psoriatic arthritis, III, Union, TNF, Trauma, Risk, Pain, Ustekinumab, Risk factor, Safety, Patient, Arthritis, Disease, Nail disease, Therapy, Psoriasis, Ageing, Clinical trial, Woman, Obesity, Pharmaceutical industry, Tildrakizumab, Bimekizumab, Phase, Epidemiology

The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation.
  • Psoriatic arthritis occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years.
  • In recent years, women have contributed more to the global psoriatic arthritis treatment market as they are at greater risk of developing psoriatic arthritis.

Medzino Partners With Belle for AI-Powered Digital Skin Health

Retrieved on: 
Wednesday, June 29, 2022
Diagnosis, Acne, Dermatology, Patient, Nail disease, Vitiligo, Alopecia areata, Men's Health, Prescription, API, Melasma, Atopic dermatitis, District, Partnership, Technology, Psoriasis, Health, Physician, Skin, AI, Infection, Dermatitis, MD, Algorithm, Medical device, Medical imaging

AUSTIN, Texas and CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Medzino Health and BelleTorus Corporation ("Belle") today announced Medzino's licensing of Belle's skin AI technology for Medzino's digital healthcare platform.

Key Points: 
  • AUSTIN, Texas and CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Medzino Health and BelleTorus Corporation ("Belle") today announced Medzino's licensing of Belle's skin AI technology for Medzino's digital healthcare platform.
  • The Belle skin image matching engine is secure, cloud-based and HIPAA-compliant, and is provided via API integration into partners' websites.
  • Belle provides qualitative assessment (identification) and quantitative scoring (severity) of skin conditions, with applications available for providers, patient clinical trials, and skin health product companies.
  • Belle team members in the United States, France, and Vietnam collaborate with partners worldwide to bring the power of AI to digital skin healthcare.

Global Dermatology Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Health, Other Health, Psoriasis, Greg Camp, Acne, Scabies, Hyperlink, Wound healing, Cellulitis, Nail disease, Ownership, Players, A-Z, Research, Diabetic foot ulcer, Sun, Intellectual property, Rash, Technology, Finance, Venous ulcer, Rosacea, Confidentiality, Cosmetics, Veterinary medicine, Lease, Sales, Risk management, Petroleum, Property management, Practice of law, Hair loss, Plantar wart, Dermatology, Dermatitis, Angioedema, Impetigo

The "Global Dermatology Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dermatology Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dermatology Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 750 dermatology deals.
  • The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dermatology deals.
  • In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2015.

iGenomeDx Inc. Wins 2022 SBA District Minority-Owned Small Business of the Year

Retrieved on: 
Monday, May 16, 2022
Research, Genetics, Professional Services, Small Business, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Physician, COVID-19, Immunology, Health, DNA, Nail disease, Patient, Microbiology, South Texas Medical Center, Urinary system, Disulfiram-like drug, Genetic, Infection, Research, FDA, San Antonio District, Compliance, Technology, SBA, Small business, Small Business Week, Therapeutic drug monitoring, CEO, Medical device, Pharmaceutical industry, Vaccine, Genomics

iGenomeDx Inc ., the molecular diagnostic laboratory that works to use DNA to match individuals to specific medications, won this years San Antonio District SBA Minority-Owned Small Business of the Year.

Key Points: 
  • iGenomeDx Inc ., the molecular diagnostic laboratory that works to use DNA to match individuals to specific medications, won this years San Antonio District SBA Minority-Owned Small Business of the Year.
  • The San Antonio District Office of the U.S. Small Business Administration (SBA) and the Texas South-West Small Business Development Center (SBDC) announced the award earlier this spring and honored Small Business Week winners early in May .
  • iGenomeDx offers DNA-based pharmacogenomic tests to guide physicians to the most effective medication among the choices available based on an individuals genetic makeup, effectively personalizing medicine.
  • Such technology will help avoid trial and error, reduce hospitalizations due to adverse drug reactions, and reduce the cost of healthcare.

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

Retrieved on: 
Monday, March 28, 2022
FAAD, Face, LinkedIn, Safety, Form 10-K, IGA, MA, Forward-looking statement, Skin, SEC, Doctor of Philosophy, Risk, Webcast, Ageing, Standard of care, Scalp, Q&A, Dermatology, EST, Psoriasis, Nail disease, Prevalence, Week, MD, Dermatitis, New, Review, Twitter, JAK1, Nasdaq, U.S. Securities and Exchange Commission, Mark (given name), GLOBE, Physician, NDA, FDA, Acne, Atopic dermatitis, Patient, Hair, Renewable energy, Pharmaceutical industry, Cosmetics, Risk management

This year will be transformational for Arcutis.

Key Points: 
  • This year will be transformational for Arcutis.
  • An archived replay of the webcast will be available on the Arcutis website following the event.
  • For more information, visit www.arcutis.com or follow Arcutis on LinkedIn and Twitter .
  • We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole

Retrieved on: 
Thursday, July 1, 2021
Infectious diseases, Medical specialties, Medicine, Nail disease, Onychomycosis, Mycosis, Nail, Antifungal, Fosravuconazole

This active principle,a triazole antifungal compound discovered by Kaken Pharmaceutical, is indicated for the treatment of onychomycosis, a fungal infection of the nail.

Key Points: 
  • This active principle,a triazole antifungal compound discovered by Kaken Pharmaceutical, is indicated for the treatment of onychomycosis, a fungal infection of the nail.
  • Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties.
  • Global prevalence of onychomycosis is estimated to be around 5.5%[1] and the condition is responsible for 50% of all consultations for nail disorders[2].
  • Under the agreement, Kaken Pharmaceutical receives an upfront cash payment and has the potential to receive milestone payments and royalties on the net sales of the product.